Novel ghrelin analogs with improved stability, selectivity, and duration of action were developed and characterized, advancing ghrelin-based drug development for GH deficiency, appetite disorders, and cardiovascular protection.
Key findingMultiple novel ghrelin analogs were designed with improved pharmacokinetic properties (longer half-life, better stability) and selectivity profiles co
What the researchers found
Multiple novel ghrelin analogs were designed with improved pharmacokinetic properties (longer half-life, better stability) and selectivity profiles compared to native ghrelin, maintaining GH-releasing and appetite effects in animal models.
Why it matters
Advances understanding of ghrp, peptide-design, bioavailability with translational implications.
How the study worked
animal-study study examining ghrp and peptide-design.
What this study cannot tell us
Study-specific limitations apply; see abstract for details.
How to read the evidence
preliminary evidence from animal-study study design.
When this study was published
Published in 2004.
The bigger picture
Contributes to the growing body of peptide research with implications for clinical development and therapeutic applications.
Questions still open
- Further research needed to confirm and extend these findings.
- Clinical translation and safety need evaluation.
- Optimal dosing and delivery require characterization.
Common questions
What was the main focus of this study?
What was discovered?
Read the original research
Novel analogs of ghrelin: physiological and clinical implications.
European journal of endocrinology, 151 Suppl 1, S71-5
Citation
Halem, Heather A; Taylor, John E; Dong, Jesse Z; Shen, Yeelana; Datta, Rakesh; Abizaid, Alfonso; Diano, Sabrina; Horvath, Tamas; Zizzari, Philippe; Bluet-Pajot, Marie-Thèrèse; Epelbaum, Jacques; Culler, Michael D. (2004). Novel analogs of ghrelin: physiological and clinical implications.. European journal of endocrinology, 151 Suppl 1, S71-5.